This 2019 report from the Prescription Drug Monitoring Program (PDMP) Training and Technical Assistance Center provides guidance to PDMP administrators on how to create standard procedures to share de-identified PDMP data with researchers for public health surveillance, research,
Technical Assistance Guide: Prescription Drug Monitoring Programs Administrators’ Orientation Package
Source: Prescription Drug Monitoring Program Training and Technical Assistance Center
This 2018 report is a comprehensive guide on how to design, implement, and manage a state Prescription Drug Monitoring Program (PDMP). Produced by the PDMP Training and Technical Assistance Center at Brandeis University, the guide includes a history of PDMPs, a review of state
Prescription Behavior Surveillance System Issue Brief
Source: CDC National Center for injury Prevention and Control and Brandeis University
This 2017 data brief from the Prescription Behavior Surveillance System compares trends in synthetic opioid overdose deaths in 5 states to trends in law enforcement reports on fentanyl and prescriptions for fentanyl in those states. A product of the Prescription Drug Monitoring Program Center of Evidence at Brandeis University.
Prescription Behavior Surveillance System: Prescription Drug Monitoring Program Center of Excellence
Source: Prescription Monitoring Program Center of Excellence at Brandeis
This brief describes the purpose of the Prescription Behavior Surveillance System (PBSS) project at the Prescription Drug Monitoring Program (PDMP) Center of Excellence at Brandeis University. The PBSS collects data from state PDMPs and analyzes the data to guide state policy decisions regarding prescription controlled substances.
CMS Roadmap: Fighting the Opioid Crisis
Source: Centers for Medicare & Medicaid Services
This 4 page document briefly summarizes the Centers for Medicare & Medicaid Services strategy for fighting the opioid crisis including their initiatives in prevention, treatment, and data analysis.
Guidance to States: Treatment Standards for Women with Substance Use Disorders
Source: The National Association of State Alcohol and Drug Abuse Directors
This 2008 publication from the National Association of State Alcohol/Drug Abuse Directors defines treatment standards for women with substance use disorders (SUD). The publication can be used by SUD treatment providers or by states seeking to improve their delivery of SUD treatment services.
PBSS Data Brief: Patient Risk Measures for Controlled Substance Prescriptions in Maine, 2010-2014
Source: Prescription Behavior Surveillance System - Brandeis University
The Prescription Behavior Surveillance System (PBSS) collects deindentified data from state prescription drug monitoring programs (PDMPs) to identify trends in controlled substance prescribing and dispensing and indicators of non-medical use and diversion. This 2015 report summarizes the data from Maine’s PDMP.
Monitoring and Changing Behavior: The Role of PMP Data in Kentucky Drug Courts
Source: Prescription Monitoring Program Center of Excellence at Brandeis
A 2011 report about how Kentucky’s drug courts access and use data from the state’s prescription drug monitoring program (PDMP) from the PDMP Center of Excellence at Brandeis University.
PBSS Data Brief: Patient Risk Measures for Controlled Substance Prescriptions in Idaho, 2012-2014
Source: Prescription Behavior Surveillance System - Brandeis University
The Prescription Behavior Surveillance System (PBSS) collects deindentified data from state prescription drug monitoring programs (PDMPs) to identify trends in controlled substance prescribing and dispensing and indicators of non-medical use and diversion. This 2016 report summarizes the data from Idaho’s PDMP.
PBSS Issue Brief: Geographic Patterns in Neonatal Abstinence Syndrome and Prescription Opioids in Kentucky
Source: Prescription Behavior Surveillance System - Brandeis University
The Prescription Behavior Surveillance System (PBSS) collects deindentified data from state prescription drug monitoring programs (PDMPs) to identify treads in controlled substance prescribing and dispensing and indicators of non-medical use and diversion. This 2016 report looks at the